Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) is a clinical-stage biotechnology company developing small-molecule molecular glue degraders (MGDs), which recruit natural protein-destruction mechanisms to selectively degrade disease-related proteins. Its QuEEN discovery engine combines AI and machine learning,… From the company’s description.
Over the twelve months to Sep 30, 2026, Monte Rosa Therapeutics, Inc. reported revenue of $70.33M, down 61.3% from a year earlier, and a net loss of $130.97M. Its operating margin was −214.5%, and operations used $165.47M in cash. In fiscal 2025, it reported revenue of $123.67M, up 63.5% from fiscal 2024, and a net loss of $38.63M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Monte Rosa Therapeutics, Inc. does
In the company’s own words
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) is a clinical-stage biotechnology company developing small-molecule molecular glue degraders (MGDs), which recruit natural protein-destruction mechanisms to selectively degrade disease-related proteins. Its QuEEN discovery engine combines AI and machine learning, experimental screening, proteomics and a proprietary library of more than 75,000 MGD molecules to identify targets and design drug candidates. The company’s clinical programs include MRT-6160, targeting VAV1 for immune-mediated diseases; MRT-8102, targeting NEK7 for inflammatory diseases; and MRT-2359, targeting GSPT1 for metastatic castration-resistant prostate cancer. It is also advancing preclinical programs against CCNE1 and CDK2. Monte Rosa licenses VAV1-directed MGDs to Novartis and collaborates with Novartis and Roche on additional discovery programs; it retains rights to its other disclosed pipeline programs. The company focuses on immunology, inflammation, cardiovascular disease and oncology. Monte Rosa Therapeutics was incorporated in 2019, following the incorporation of its Swiss operating subsidiary in 2018. Its website is www.monterosatx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1826457
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Monte Rosa Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Monte Rosa Therapeutics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Monte Rosa Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Monte Rosa Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Monte Rosa Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Monte Rosa Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”